Tarsus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TARS research report →
About the company
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease.
- CEO
- Bobak R. Azamian
- IPO
- 2020
- Employees
- 323
- HQ
- Irvine, CA, US
Price Chart
- Market Cap
- $2.82B
- P/E
- -57.40
- P/S
- 5.26
- P/B
- 8.06
- EV/EBITDA
- -69.73
- Div Yield
- 0.00%
- Gross Margin
- 90.44%
- Op Margin
- -9.50%
- Net Margin
- -9.02%
- ROE
- -14.19%
- ROIC
- -11.54%
- Revenue
- $451.36M · 146.71%
- Net Income
- $-66,418,000 · 42.52%
- EPS
- $-1.59 · 48.21%
- Op Income
- $-70,969,000
- FCF YoY
- 73.63%
- 52W High
- $85.25
- 52W Low
- $38.51
- 50D MA
- $62.15
- 200D MA
- $68.68
- Beta
- 0.51
- Avg Volume
- 745.34K
Get TickerSpark's AI analysis on TARS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Goodrich Katherine | other | 3,837 |
| Jun 25, 26 | Goodrich Katherine | other | 2,417 |
| Jun 25, 26 | Goldberg Andrew D. | other | 3,837 |
| Jun 25, 26 | Goldberg Andrew D. | other | 2,417 |
| Jun 25, 26 | Morrison Scott W | other | 3,837 |
| Jun 25, 26 | Morrison Scott W | other | 2,417 |
| Jun 25, 26 | CHAUDHURI BHASKAR | other | 3,837 |
| Jun 25, 26 | CHAUDHURI BHASKAR | other | 2,417 |
| Jun 25, 26 | YARNO WENDY L | other | 3,837 |
| Jun 25, 26 | YARNO WENDY L | other | 2,417 |
Our TARS coverage
Recent articles, reports, and earnings notes.
No research on TARS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TARS report →Similar companies
Peers in the same neighborhood.